Tagged with AstraZeneca,

Coronavirus IFPMA Director General Thomas B. Cueni shares the outcomes of a recent high level pharma industry media briefing on the search for a COVID-19 treatment; highlighting the unprecedented levels of collaboration being demonstrated as key industry players work towards a common goal.*   Last week, high-level representatives from seven companies…

Belgium Anne-Laure Dreno, country president of AstraZeneca in Belgium, elaborates on the significant position Belgium and the local affiliate have for the group as a frontrunner in innovative areas such as creating value-based agreements for reimbursements, (clinical) research and development, and embracing the opportunities of patient data. Dreno also discusses her…

UAE Ousama Al Haj, director for UAE, Bahrain, Oman & Qatar at AstraZeneca, highlights the company’s substantial growth and favourable position in the Gulf markets, explains how the company is overcoming the local healthcare dynamics by partnering with local authorities to offer patients’ platforms instead of products, and analyzes AstraZeneca’s future…

Sweden Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real titan of life sciences.* The country that has introduced some of the most impactful healthcare inventions of the 20th century…

Czech Republic Emelie Antoni joined AstraZeneca in Sweden 20 years ago, evolving in global, regional and local roles. Last year, she became country manager for Czech Republic & Slovakia, with an ambitious plan to triple revenues during her tenure. She lays down the pillars of her plan, discusses the evolving role of…

Sweden Michelle Werner, country president for AstraZeneca’s Nordics and Baltics region, highlights the company’s strong connections with local stakeholders due to its historic roots and large footprint in Sweden. Werner also discusses how the organization, which employs nearly 7,000 people in the country, plays an integral part in ensuring that patients…

Sweden Anders Ekblom is the former EVP Global Medicines Development AstraZeneca and CEO of AstraZeneca AB Sweden and is currently the Vice Chairman of the Board of LEO Pharma A/S. Additionally, he also occupies board positions on many biotech companies (Elypta, Alligator Bioscience AB, Mereo Biopharma Group Plc, AnaMar Medical AB).…

Egypt On Tuesday, February 12th, Pharmaboardroom attended a breakfast event hosted by the British Egyptian Business Association (BEBA) on competition law at the Cairo Semiramis Intercontinental Hotel. The theme for the event was competition law and its application in the Egyptian market, with the topic being introduced through a speech by…

France On January 21st, 2019, AstraZeneca inaugurated the extension of the group’s industrial site in the city of Dunkirk in Northern France. The launch was attended by Secretary of State to the Minister of the Economy and Finance, Agnès Pannier-Runacher, as part of the promotional event ‘Choose France,’ designed to promote…

UK Yesterday, pharma giant AstraZeneca announced that they have halted investment in the UK due to lack of clarity on trading regulations during this time of Brexit uncertainty. “If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest,” Leif…

AstraZeneca Gwenael Meneux of AstraZeneca Hong Kong and Macau gives his initial impression of the HK market, outlines his unusual career trajectory and the new innovations AZ is looking to bring to patients in the region.   Gwenael, you have a very interesting and diverse background that is a bit atypical…

UK The UK country managers of some of the biggest global pharma companies explain what it takes to manage in the UK market.   Erik Nordkamp, Pfizer Erik Nordkamp, the Dutch national serving as managing director of Pfizer UK and the newly-appointed president of the ABPI, likens managing a UK affiliate…